PipelineReview.com5d
Radiant Bio Closes $35 Million Series A Financing to Advance Therapeutic Pipeline with Its Proprietary Multabody™ Platform
Funding co-led by the Bill & Melinda Gates Foundation and Amplitude Ventures to advance a new class of multi-functional biologics ...
PipelineReview.com5d
Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers
PARIS, France, and HOUSTON, TX, USA I 12, 2024 I As part of its effort to develop innovative treatments for people living with rare cancers, Sanofi ...
PipelineReview.com4d
Fulcrum Therapeutics Announces Topline Results from Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)
Losmapimod failed to show an improvement in relative surface area (RSA), a measure of reachable workspace (RWS), versus placebo at week 48 ― ...
PipelineReview.com5d
Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU
PARIS, France and TARRYTOWN, NY, USA I 11, 2024 I A Dupixent (dupilumab) confirmatory phase 3 study (LIBERTY-CUPID Study C) met the primary and key ...
PipelineReview.com4d
HotSpot Therapeutics Presents First-in-Human Phase 1 Clinical Data on its Novel CBL-B Inhibitor, HST-1011, at ESMO Congress 2024
BOSTON, MA, USA I 12, 2024 I HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small molecule ...
PipelineReview.com4d
Nona Biosciences Enters into Collaboration Agreement with Umoja Biopharma to Advance In Vivo CAR-T Cell Therapies
CAMBRIDGE, MA, USA I 12, 2024 I Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to ITM), announced ...
PipelineReview.com4d
Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma
Bel-sar Demonstrated 80% Tumor Control Rate, 90% Visual Acuity Preservation, and a Highly Favorable Safety Profile ...
PipelineReview.com4d
Kriya Highlights Positive Preclinical Data for KRIYA-586, a Gene Therapy Product Candidate for Thyroid Eye Disease (TED), at ESOPRS Annual Meeting
Preclinical data demonstrate pharmacodynamic activity of KRIYA-586, an investigational gene therapy which encodes for an anti-IGF1R antibody – ...
PipelineReview.com5d
Depemokimab late-breaking data presented at ERS show a 54% reduction in severe asthma exacerbations
LONDON, UK I 09, 2024 I GSK plc (LSE/NYSE: GSK) today presented the full results from the SWIFT-1 and SWIFT-2 phase III clinical trials which ...
PipelineReview.com5d
ITM Obtains Exclusive Worldwide License from Debiopharm for CA IX-Targeted Peptide-based Radiopharmaceutical Programs Targeting Solid Tumors
MUNICH & GARCHING, Germany & LAUSANNE, Switzerland I 12, 2024 I ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical ...
PipelineReview.com4d
Kine Sciences Announces First Patient Dosed in the Phase 1b/2a Study in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
SEOUL, South Korea I 13, 2024 I Kine Sciences, a clinical-stage, biopharmaceutical company developing small peptides for immune-mediated ...
PipelineReview.com7d
AbbVie Showcases Advancement of Solid Tumor Pipeline at ESMO 2024, with New Data in Tumor Types with High Unmet Needs
NORTH CHICAGO, IL, USA I 9, 2024 I AbbVie (NYSE: ABBV) today announced that new data from its innovative antibody-drug conjugate (ADC) platform will ...